TriangleONC206 (NCT07282587)
ONC206 trial for Advanced Pheochromocytoma and Paraganglioma (NCT07282587). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with pheochromocytoma or paraganglioma that cannot be removed surgically, after standard care failed, was unsuitable or was declined. Prior ONC206 or dordaviprone is excluded.
The idea: test ONC206, an oral drug that blocks DRD2 survival signals and activates ClpP, disrupting proteins in cells' energy-producing structures. The first stage uses 150 milligrams twice daily on three consecutive days weekly. A later dose comparison proceeds only if response goals are met.
This phase 2 study plans 90 patients. Jazz Pharmaceuticals sponsors it; nine US locations list recruitment.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.